Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Antisense—down, but not out

Abstract

Learning from past failures, could firms developing antisense drugs stage a comeback?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bedikian, A.Y. et al. J. Clin. Oncol. 24, 4738–4745 (2006).

    Article  CAS  Google Scholar 

  2. Chi, K.N. et al. J. Natl. Cancer Inst. 97, 1287–1296 (2005).

    Article  CAS  Google Scholar 

  3. Levine, B.L. et al. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).

    Article  CAS  Google Scholar 

  4. Warfield, K.L. et al. PloS Pathog. 2, e1 (2006).

    Article  Google Scholar 

  5. Fortin, M. et al. Oligonucleotides. 16, 203–212 (2006).

    Article  CAS  Google Scholar 

  6. Grim, D. et al. Nature 441, 537–541 (2006).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Related links

Related links

Related links in Nature Research

Negotiating the RNAi patent thicket

Lessons learnt from Genasense's failure

Web links

Isis Pharmaceuticals

AVI BioPharma

Genta

Lorus Therapeutics

Topigen

Oncogenex

VIRxSYS

Rights and permissions

Reprints and permissions

About this article

Cite this article

Potera, C. Antisense—down, but not out. Nat Biotechnol 25, 497–499 (2007). https://doi.org/10.1038/nbt0507-497

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0507-497

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing